Literature DB >> 22895069

Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells.

Wensheng Yang1, Xiaolu Yang, Gregory David, Jay F Dorsey.   

Abstract

Among proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines. In response to gamma radiation, the expression of Sin3B and Mad4 in GBM cells was upregulated in parallel over time, suggesting that Sin3B may play a role in the regulation of Mad4 stability. In agreement with this hypothesis, exogenously expressed Sin3B significantly stabilized co-transfected Mad4 and, to a lesser extent, endogenous Mad4. In addition, siRNA silencing of Sin3B induced an increase in the expression of c-Myc and Sin3A, which contributed to increased expression of Mad4. Simultaneous silencing of Sin3B, Sin3A and c-Myc decreased Mad4 stability to a greater extent than silencing of Sin3B alone. Although Mad1 was reported to be a target of c-IAP1 E3 ligase activity for degradation, the E3 ligase activity of c-IAP1 was not required for downregulation of Mad4 expression. The association of c-IAP1 with Sin3B or Mad4 suggested that Sin3B might interfere with the binding of c-IAP1 to Mad4; however, overexpression of Sin3B did not affect the interaction between Mad4 and c-IAP1. Instead, direct binding of Sin3B to c-IAP1 may protect Mad4 from degradation by c-IAP1, leading to enhanced stability of Mad4. Exogenous expression of Sin3B also inhibited c-IAP1-mediated degradation of Mad1, TRAF2, c-IAP2 and ASK1, known targets of c-IAP1 E3 ligase activity. These results indicate that Sin3B, together with other c-Myc regulatory members, maintain the steady-state level of Mad4, in part through inhibition of c-IAP1-mediated degradation of Mad4.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895069      PMCID: PMC3493442          DOI: 10.4161/cbt.21814

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

1.  Ras enhances Myc protein stability.

Authors:  R Sears; G Leone; J DeGregori; J R Nevins
Journal:  Mol Cell       Date:  1999-02       Impact factor: 17.970

2.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

Authors:  M K Mateyak; A J Obaya; S Adachi; J M Sedivy
Journal:  Cell Growth Differ       Date:  1997-10

3.  A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci.

Authors:  Petar Jelinic; Jessica Pellegrino; Gregory David
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

4.  TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2.

Authors:  Xiaoming Li; Yili Yang; Jonathan D Ashwell
Journal:  Nature       Date:  2002-03-21       Impact factor: 49.962

5.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

Authors:  Yan Wang; Ingo H Engels; Deborah A Knee; Marc Nasoff; Quinn L Deveraux; Kim C Quon
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

6.  hMad4, c-Myc endogenous inhibitor, induces a replicative senescence-like state when overexpressed in human fibroblasts.

Authors:  Richard Marcotte; Jing-Fang Qian; James Chen; Eugenia Wang
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

7.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

Authors:  Zirong Li; Sara Van Calcar; Chunxu Qu; Webster K Cavenee; Michael Q Zhang; Bing Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

Review 8.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

9.  RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.

Authors:  Mikkel Noerholm; Leonora Balaj; Tobias Limperg; Afshin Salehi; Lin Dan Zhu; Fred H Hochberg; Xandra O Breakefield; Bob S Carter; Johan Skog
Journal:  BMC Cancer       Date:  2012-01-17       Impact factor: 4.430

10.  Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts.

Authors:  D Perna; G Fagà; A Verrecchia; M M Gorski; I Barozzi; V Narang; J Khng; K C Lim; W-K Sung; R Sanges; E Stupka; T Oskarsson; A Trumpp; C-L Wei; H Müller; B Amati
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

View more
  5 in total

1.  Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells.

Authors:  Wensheng Yang; Mariana Cooke; Colin S Duckett; Xiaolu Yang; Jay F Dorsey
Journal:  Cell Cycle       Date:  2014-01-22       Impact factor: 4.534

2.  Stress-mediated Sin3B activation leads to negative regulation of subset of p53 target genes.

Authors:  Rama Kadamb; Shilpi Mittal; Nidhi Bansal; Daman Saluja
Journal:  Biosci Rep       Date:  2015-06-25       Impact factor: 3.840

Review 3.  Targeting the Ubiquitin System in Glioblastoma.

Authors:  Nico Scholz; Kathreena M Kurian; Florian A Siebzehnrubl; Julien D F Licchesi
Journal:  Front Oncol       Date:  2020-11-25       Impact factor: 6.244

4.  Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.

Authors:  Zhi-Gang Zhu; Lei Chen; Dong-Liu Miao; Yiqi Jin; Qiong Wu
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

Review 5.  Future paradigms for precision oncology.

Authors:  Giannoula Lakka Klement; Knarik Arkun; Dalibor Valik; Tina Roffidal; Ali Hashemi; Christos Klement; Paolo Carmassi; Edward Rietman; Ondrej Slaby; Pavel Mazanek; Peter Mudry; Gabor Kovacs; Csongor Kiss; Koen Norga; Dobrin Konstantinov; Nicolas André; Irene Slavc; Henk van Den Berg; Alexandra Kolenova; Leos Kren; Jiri Tuma; Jarmila Skotakova; Jaroslav Sterba
Journal:  Oncotarget       Date:  2016-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.